Newronika

The brain leads. Therapy adapts.

Milan, Italy · Founded 2016 · $25.7M raised

Headquarters
Milan
Employees
11–50
Founded
2016
Business Model
B2B
Total Funding
$25.7M
Last Round
$15.9M Series BFeb 2025
Rounds
2

About

Newronika develops αDBS, an adaptive deep brain stimulation platform for Parkinson's disease that senses full-spectrum brain signals every ten minutes and automatically adjusts stimulation to keep patients in their therapeutic window. The CE-marked, clinically validated system is built on a patented proportional control algorithm and a cloud-based platform called WebBioBank that stores longitudinal neural data to continuously refine therapy. In a first-of-its-kind double-blind randomized crossover clinical trial, 86% of patients preferred αDBS over conventional DBS.

Summary

Newronika is a Biotech company based in Milan, Italy, founded in 2016. It has raised $25.7M in total across 2 rounds, most recently a $15.9M Series B round in Feb 2025. Investors include Omnes Capital, Indaco Venture Partners and Innogest Capital.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BFeb 2025
$15.9M

Sign up to see all 2 rounds

Series A through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Newronika on Indexed.vc
<a href="https://indexed.vc/companies/newronika"><img src="https://indexed.vc/api/badge/company/newronika" alt="Newronika on Indexed.vc" width="260" height="76" /></a>